What is AskBio?
AskBio operates as a fully integrated molecular medicine and technology enterprise, specializing in the research, development, and manufacturing of gene therapies. The company maintains a diverse pipeline targeting complex conditions, including neuromuscular, central nervous system, metabolic, and cardiovascular diseases. With over 775 patents and a global network of research and manufacturing facilities—spanning North America and Europe—AskBio is uniquely positioned to address unmet medical needs through synthetic biology and advanced genetic engineering. As an independently operated subsidiary of Bayer, the firm benefits from significant operational synergies while maintaining its focus on pioneering clinical-stage therapeutic solutions.
How much funding has AskBio raised?
AskBio has raised a total of $4.2M across 2 funding rounds:
Grant
$1.6M
Grant
$2.6M
Grant (2004): $1.6M with participation from Muscular Dystrophy Association
Grant (2020): $2.6M led by Scottish Enterprise
Key Investors in AskBio
Muscular Dystrophy Association
The Muscular Dystrophy Association is a non-profit organization dedicated to combating neuromuscular diseases by funding critical research and providing essential community services.
Scottish Enterprise
Scottish Enterprise is a national economic development agency that supports business growth and innovation through strategic investment and public-private partnerships.
What's next for AskBio?
Looking ahead, the strategic deployment of the $2.6M investment is expected to focus on the maturation of AskBio's clinical pipeline and the optimization of its cGMP manufacturing capabilities. By scaling its synthetic DNA production and refining its viral vector delivery platforms, the company aims to expedite the transition of its candidates from the laboratory to the patient. The focus remains on maintaining its competitive edge in the gene therapy market, ensuring that its expansive library of molecular tools continues to drive innovation in precision medicine. As the company integrates further with its parent entity, the emphasis will likely shift toward global commercialization strategies and the long-term sustainability of its therapeutic programs.
See full AskBio company page
